newsfilter
← Earnings
Earnings Releases·

Vycor Medical — Three and Nine Months Ended September 30, 2026 Earnings Summary

  • Total revenue declined 19% year-over-year to $414,895 for the quarter and 11% to $1,291,699 for the nine months, driven primarily by an 18% drop in the Vycor Medical division, while NovaVision revenue rose 41% in the quarter but fell 11% over the nine months.
  • Gross profit margins contracted slightly to 85% for the quarter and 83% for the nine months, with GAAP operating profit increasing to $80,083 for the nine-month period despite a 12% decline in gross profit year-over-year.
  • Net losses widened for the nine-month period to $(325,812) GAAP and $(280,144) Non-GAAP, though Non-GAAP cash operating expenses decreased 11% to $946,864 compared to the prior year.
  • Strategic progress includes the publication of four new peer-reviewed studies on the ViewSite™ Brain Access System (VBAS) this year, bringing total clinical papers to 54, alongside a stable share count of 33,372,796.
  • Revenue fluctuations in the Vycor Medical division are attributed to elevated 2025 sales from new hospital adoptions and bulk orders, while international sales remain characterized by irregular, "lumpy" large orders.